Gilead

Gilead, is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. Their goal is to discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases. For more information, visit: https://www.gilead.com/  

TRODELVY ACCESS SERVICES is a patient access and reimbursement support program. It will help you understand specific coverage and reimbursement guidelines for TRODELVY^® (sacituzumab govitecan-hziy)  180mg single-dose vial.  For full Prescribing Information, including boxed Warning, please visit https://trodelvy.com/pdf/PrescribingInformation.pdf.